Sanofi's tolebrutinib drug delays progressive MS by 31% in trial
WEB2 days ago · Tolebrutinib, from the $3.7 billion takeover of Principia in 2020, ... Reuters, the news and media division of Thomson Reuters, is the world’s largest multimedia news provider, reaching billions ...
Novel Agent First to Slow Disability in nrSPMS - Medscape
WEB2 days ago · September 20, 2024. 0. 0. COPENHAGEN, Denmark — A new investigational drug has become the first agent to slow disability in patients with nonrelapsing secondary progressive multiple sclerosis ...
Press Room - Sanofi US News
WEB3 days ago · A small (0.5%) proportion of participants in the tolebrutinib group experienced peak ALT increases of >20xULN, all occurring within the first 90 days of treatment. Deaths were balanced across the teriflunomide and tolebrutinib arms, at 0.2% and 0.1% respectively, and were assessed as unrelated to treatment by investigator.
Sanofi lifts lid on data behind tolebrutinib’s mixed MS studies
WEB2 days ago · Sanofi’s safety and tolerability analysis showed 4.1% of people on tolebrutinib had liver enzyme levels of at least three times the upper limit of normal, compared to 1.6% of the patients taking ...
Tolebrutinib Shows Positive Results in Slowing Disability …
WEB3 days ago · Newly announced late-breaking results from the phase 3 HERCULES trial (NCT04411641) showed that tolebrutinib (Sanofi), a Bruton’s tyrosine kinase (BTK) inhibitor, had a significant effect on disability accumulation compared with placebo in patients with non-relapsing secondary progressive multiple sclerosis (nrSPMS). Presented at the 2024 European Committee for Treatment and Research in ...
Tolebrutinib: New Sanofi’s Brain-Penetrant BTK Inhibitor | Sanofi
WEBFeb 23, 2023 · New data for tolebrutinib, Sanofi’s investigational brain-penetrant BTK inhibitor, showed significant effect on CNS immune mediators that drive MS disease progression
Tolebrutinib clinical trial program update - Sanofi
WEBAug 8, 2017 · The relapsing MS trials in the tolebrutinib clinical trial program, GEMINI I and GEMINI II, are now fully enrolled. Regulatory timelines for this indication remain unchanged with submission in relapsing MS expected in 2024.
Sanofi's tolebrutinib cuts MS progression by 31% in trial
WEB2 days ago · While on the whole, tolebrutinib was well-tolerated, there was a higher proportion of elevated liver enzymes with the drug compared to placebo, 4.1% versus 1.6%, which can indicate liver toxicity.
BTK Inhibitor Tolebrutinib Slows Disability Progression in Phase 3 ...
WEBSep 3, 2024 · Tolebrutinib, a brain-penetrant BTK inhibitor, achieved the primary endpoint in the HERCULES study, significantly reducing disability accumulation in patients with non-relapsing secondary progressive multiple sclerosis.
Sanofi's Tolebrutinib Delays Disability Progression In Patients …
WEB2 days ago · The data demonstrated that tolebrutinib delayed the time to onset of 6-month confirmed disability progression (CDP) by 31% compared to placebo (HR 0.69; p=0.0026).
Skip to content